Zumutor Biologics is an innovative biotech company focused on developing proprietary monoclonal antibodies for cancer immunotherapy and precision oncology. Based in Hyderabad, Zumutor’s technology platforms harness the human immune system to target and eliminate cancer cells, aiming for breakthroughs in solid tumor and hematological malignancy treatment.
Zumutor’s antibodies are supported by international patents and preclinical/clinical validation. The company collaborates with pharmaceutical giants and academic centers globally, pushing the frontiers of immuno-oncology and transformative cancer care.
Key Technologies & Products:
-
Monoclonal antibody therapeutics for cancer
-
Proprietary platforms enabling immune modulation
-
Preclinical and clinical product pipeline
-
International research partnerships
Achievements & Highlights:
-
Multiple immuno-oncology candidates advancing to clinical trials
-
International patent portfolio for core technologies
